



Correction to: Camrelizumab: First Global Approval

Anthony Markham¹ · Susan J. Keam¹

Published online: 24 August 2019
© Springer Nature Switzerland AG 2019

Correction to: Drugs (2019) 79 (12):1355–1361
<https://doi.org/10.1007/s40265-019-01167-0>

Page 1355, Abstract, Inline table ‘Camrelizumab (AiRuiKa™): Key Points’, and Introduction

Where it currently reads Camrelizumab (AiRuiKa™), it should read:

Camrelizumab (AiRuiKa®).

Page 1355, Inline table ‘Camrelizumab (AiRuiKa™): Key Points’

The third row, which currently reads:

First global approval on 31 May 2019 in China.

Should read:

First global approval on 29 May 2019 in China.

Page 1361, Section 3 Current Status, which currently reads:

Camrelizumab received its first global approval on the 31 May 2019 in China for the treatment of patients with relapsed or refractory classical Hodgkin lymphoma who have received at least two previous systemic chemotherapies.

Should read:

Camrelizumab received its first global approval on the 29 May 2019 in China for the treatment of patients with relapsed or refractory classical Hodgkin lymphoma who have received at least two previous systemic chemotherapies.

The original article can be found online at <https://doi.org/10.1007/s40265-019-01167-0>.

✉ Anthony Markham
dru@adis.com

¹ Springer Nature, Private Bag 65901, Mairangi Bay, Auckland 0754, New Zealand